Max Hodak and Science Corporation’s Bid to Redefine Human-Machine Interaction
When most people envision interacting with technology, they picture tactile inputs: fingers on glass, keys clacking beneath wrists, or voice commands issued into the void. For Max Hodak, CEO of Science Corporation, these paradigms are already obsolete relics of a pre-neural era. Having spent his career betting that the bandwidth between human cognition and digital systems is catastrophically narrow, Hodak is now poised to present preliminary data from the first U.S. human trials of Science Corp’s biohybrid brain-computer interface (BCI) at TechCrunch Disrupt 2026. In his “Beyond Screens” session on the Disrupt Stage, he will articulate a vision where technology no longer demands adaptation from humans, but instead reshapes itself around neural signals, creating interfaces that are less about command-and-control and more about symbiotic communication. This presentation comes at a pivotal moment for the BCI field, as companies transition from engineering prototypes to clinical validation, and as investors begin to distinguish between speculative neuroscience and viable medical devices.